Expedited Reviews For China-Originated Drugs Shift Back Home

R&D, Multiple Reform Factors Likely At Play

 
• By Xu Hu
  
First half of 2024 and 2025
In H1 of both 2024 and 2025, ADC appeared as the leading modality among China-originated drugs that received expedited review programs or filed for INDs. (Shutterstock)

More from Review Pathways

More from China